List view / Grid view
Recommendation of the once-daily triple therapy increases the number of…
Recommendation of the once-daily triple therapy increases the number of eligible cystic fibrosis patients who can access treatments in the UK.
The committee’s final draft guidance cited high-cost as a key…
The committee’s final draft guidance cited high-cost as a key reason for its negative opinion of the Alzheimer’s drugs, developed by Biogen and Eisai.
The agency’s recommendation could provide eligible breast cancer patients with…
The agency’s recommendation could provide eligible breast cancer patients with a treatment that analysis suggest is to likely to work as well as two medicines already recommended by NICE.
Approximately 1,000 eligible NHS patients could benefit from the new…
Approximately 1,000 eligible NHS patients could benefit from the new endometriosis treatment annually.
The agency’s decision means eligible adult patients in the UK…
The agency’s decision means eligible adult patients in the UK are set to access the combination immunotherapy as a new treatment option for acute lymphoblastic leukaemia (ALL).
As a novel formulation, the “groundbreaking drug” is expected to…
As a novel formulation, the “groundbreaking drug” is expected to improve the quality of life for young cancer patients with hearing loss.
The first new dementia medicine to be licensed in over…
The first new dementia medicine to be licensed in over two decades shows for first time, that the course of Alzheimer disease can be modified and slow cognitive decline.
This article summarises some of the recent notable drug approvals…
This article summarises some of the recent notable drug approvals in the EU and US, including a gene therapy and an enzyme replacement therapy.
The National Institute For Health and Care Excellence (NICE)'s decision…
The National Institute For Health and Care Excellence (NICE)'s decision follows a reduction in the price of Pfizer’s small molecule treatment for sickle cell disease.
An “innovative, life-extending treatment” for BRAF V600E mutation-positive glioma has…
An “innovative, life-extending treatment” for BRAF V600E mutation-positive glioma has been recommended for certain young people on the NHS.
Clinical studies of Pfizer’s oral medicine for alopecia areata have…
Clinical studies of Pfizer’s oral medicine for alopecia areata have demonstrated response rates continued to improve for up to two years.
The first BRCA-targeted treatment has been recommended for advanced breast…
The first BRCA-targeted treatment has been recommended for advanced breast or metastatic breast cancer by the National Institute for Health and Care Excellence (NICE).
A new, easy-to-use treatment option for advanced Parkinson’s could benefit…
A new, easy-to-use treatment option for advanced Parkinson’s could benefit around 900 adult patients on the NHS, according to National Institute for Health and Care Excellence (NICE) final draft guidance.
Glofitamab is the first treatment to be recommended by the…
Glofitamab is the first treatment to be recommended by the National Institute for Health and Care Excellence (NICE) at the same time as it is approved for advanced lymphoma in the UK.
The National Institute for Health and Care Excellence (NICE) has…
The National Institute for Health and Care Excellence (NICE) has published final draft guidance on Pfizer’s Rimegepant, recommending it for the first time as a treatment for acute migraines.
